Altace Revascularization Benefit Is Clear But Inappropriate For Label - Cmte.

King Pharmaceuticals' ACE inhibitor Altace is clearly beneficial in reducing the need for revascularization, but inclusion of the claim in labeling may inappropriately influence clinical practice, members of FDA's Cardio-Renal Drugs Advisory Committee said.